MGF (5 mg Vial) Dosage Protocol
Mechano Growth Factor (MGF) is a splice variant of IGF-1 (IGF-1Ec in humans) produced in response to mechanical stress and tissue damage. Research indicates a role in muscle satellite cell activation, bone regeneration, and neurogenesis. Distinct from the PEGylated version (PEG-MGF) — MGF has a short half-life and acts as a localized tissue repair signal.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 100 mcg (0.1 mg) | 6 units (0.06 mL) |
| Week 2 | 150 mcg (0.15 mg) | 9 units (0.09 mL) |
| Week 3 | 200 mcg (0.2 mg) | 12 units (0.12 mL) |
| Week 4 | 250 mcg (0.25 mg) | 15 units (0.15 mL) |
| Weeks 5–8 | 300 mcg (0.3 mg) | 18 units (0.18 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units manageable for accuracy. For ≤10‑unit (≤0.10 mL) administrations during early titration, consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; follow the exact preparation’s validated use-by and sterile-handling instructions.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (MGF, 5 mg each) | 8 weeks ≈ 3 vials 12 weeks ≈ 5 vials 16 weeks ≈ 8 vials |
| Insulin Syringes (U‑100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle 12 weeks (5 vials): 15 mL → 2 × 10 mL bottles 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100‑count boxes 12 weeks: 168 swabs → recommend 2 × 100‑count boxes 16 weeks: 224 swabs → recommend 3 × 100‑count boxes |
Protocol Overview
Distinct from PEG-MGF — the non-PEGylated form has a short half-life (minutes) and acts as a localized tissue-repair signal rather than a systemic growth factor. Effects appear tissue-specific and transient. Preclinical data supports roles in muscle satellite cell activation, bone regeneration, and neurogenesis.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
MGF is generated through alternative splicing of the IGF-1 gene in response to mechanical loading or tissue injury. The resulting peptide contains a unique C-terminal E domain distinct from systemic IGF-1. Preclinical research demonstrates MGF activates satellite cells (muscle stem cells), promotes osteoblast proliferation, and supports neurogenesis. Effects appear localized and transient — a tissue-specific repair signal.
Potential Benefits & Side Effects
Potential Benefits
- Satellite cell activation and myoblast proliferation.
- Bone defect healing in animal models.
- Neurogenesis and neuroprotection in aging brain tissue.
Side Effect Profile
- Generally well-tolerated in preclinical settings.
- Occasional injection-site reactions.
- Long-term human safety data limited.
Lifestyle Factors
- Pair with resistance training — mechanical stimulus naturally upregulates MGF expression.
- Adequate protein intake (1.6–2.2 g/kg).
- Prioritize sleep for growth factor activity.
Injection Technique
- Subcutaneous, rotate sites.
- Time near workout for localized effect.